Animal Model Of Absence Epilepsy Research Articles

Maturational Aspects of Epilepsy Mechanisms and Consequences for the Immature Brain

Maturational Aspects of Epilepsy Mechanisms and Consequences for the Immature Brain

Design and construction of a long-term continuous video-EEG monitoring unit for simultaneous recording of multiple small animals

In recent years several new rat models of human limbic/mesial temporal lobe epilepsy have been described [1, 2, 4–7, 11, 15–17]. Unlike earlier models such as kindling in which the seizures are induced by an exogenous stimulus, these new models are characterized by seizures that occur spontaneously at random intervals. Although the spontaneity of the seizures makes these models more like human epilepsy, documentation of these seizures by direct observation is highly inefficient, and subbehavioral electrographic seizures could be missed. Continuous paper EEG and video recording have been used [5–7, 15], but these techniques are resource intensive. The slow paper speed required by long-term paper recordings limits the ability to differentiate between true seizure activity and electrical artifact. Subtle behavioral seizures are likely to be missed during rapid review of video recordings alone [16]. Ambulatory cassette EEG recordings have been used [3], but the systems require expensive proprietary hardware, and the systems have limited channels for recording (8–16). To improve the utility of the models, we developed a long-term EEG/video monitoring system to detect the electrographic seizures and document their behavioral accompaniment. The system is based on commercially available components, including a computerized EEG seizure detection system that was initially developed for human seizure monitoring [8, 9, 13]. Seizures are reliably detected and the data are reduced so that 24 h of recording can be reviewed in 30–90 min. Although the computer program is accurate, special care must be taken in system design and construction to reduce sources of electrical artifact that can cause false detections when multiple animals are recorded simultaneously on a single EEG machine. During data review it is necessary to differentiate between electrical artifact induced by animal activity from true seizure activity by key EEG patterns. Certain seizure patterns (less than 3 Hz, low amplitude) will not be detected by the seizure detection program, but the system is highly effective for typical limbic seizures and may be useful for the animal models of absence epilepsy [12, 14]. It can also be used as a continuous or intermittent EEG/physiological recording device for experiments that examine animals' spontaneous behavior and the EEG correlate (e.g. sleep/wake cycles, learning and memory tasks).

Effects of GABA B receptor antagonists on learning and memory retention in a rat model of absence epilepsy

A variety of animal models of absence epilepsy have been described and among these exists a genetically susceptible strain of rat (genetic absence epilepsy rats of Strasbourg (GAERS)). These rats produce periods of behavioural arrest with simultaneous production of cortical spike and wave discharges (SWD). GABA B receptor antagonists suppress completely the production of these spike and wave discharges. GABA B receptor ligands have also been reported to affect cognitive performance in rodents. The present study examined the cognitive performance of GAERS and the influence of GABA B receptor antagonists on this activity. Rats were injected intraperitoneally once per day with saline or a GABA B receptor antagonist (CGP 36742 (3-amino-propyl- n-butyl-phosphinic acid) 100 mg/kg; CGP 56433 ([3-{1-( S)-[{3-(cyclohexylmethyl)hydroxy phosphinyl]-2-( S) hydroxy propyl] amino]ethyl]benzoic acid) ([3-{1-( S)-[{3-(cyclohexylmethyl)hydroxy phosphinyl]-2-( S) hydroxy propyl] amino]ethyl]benzoic acid) 1 mg/kg or CGP 61334 ([3-{[3-[(diethoxymethyl)hydroxy phosphinyl]propyl] amino}methyl]-benzoic acid (1 mg/kg). A two-way active avoidance test paradigm with negative reinforcement was used. Untreated GAERS performed significantly better than non-epileptic rats ( P<0.05) and this enhancement in cognitive performance was sustained in rats treated with the GABA B receptor antagonists.

Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists.

In 1987, 25 years after the synthesis of the potent and selective GABAB agonist baclofen (1), Kerr et al. described the first GABAB antagonist phaclofen 2. However, phaclofen and structurally similar derivatives 3-5 did not cross the blood-brain barrier and hence were inactive in vivo as central nervous system agents. As a consequence, the therapeutic potential of GABAB antagonists remained unclear. In exploring GABA and baclofen derivatives by replacing the carboxylic acid residue with various phosphinic acid groups, we discovered more potent and water soluble GABAB antagonists. Electrophysiological experiments in vivo demonstrated that some of the new compounds were capable of penetrating the blood-brain barrier after oral administration. Neurotransmitter release experiments showed that they interacted with several presynaptic GABAB receptor subtypes, enhancing the release of GABA, glutamate, aspartate, and somatostatin. The new GABAB antagonists interacted also with postsynaptic GABAB receptors, as they blocked late inhibitory postsynaptic potentials. They facilitated the induction of long-term potentiation in vitro and in vivo, suggesting potential cognition enhancing effects. Fifteen compounds were investigated in various memory and learning paradigms in rodents. Although several compounds were found to be active, only 10 reversed the age-related deficits of old rats in a multiple-trial one-way active avoidance test after chronic treatment. The cognition facilitating effects of 10 were confirmed in learning experiments in Rhesus monkeys. The novel GABAB antagonists showed also protective effects in various animal models of absence epilepsy.

Petit Mal Epilepsy: A Review and Integration of Recent Information

Petit mal (absence) epilepsy remains one of the most enigmatic of neurological disorders, and there is no widely accepted theory of its etiology. This review covers some of the current issues concerned with the disorder, including treatment and prognosis, neurochemical research, behavioral and psychophysiological effects of wave-spiked discharges, and EEG studies of seizure control. With respect to treatment, although effective drug therapy (valproic acid, ethosuximide) exists for the "pure" form of absence epilepsy, other forms, in which there is an admixture of grand mal seizures, are less amenable to pharmacotherapy. Moreover, the frequency of fatal hepatic toxicity following valproic acid therapy has been estimated at 1 in 20,000. With respect to prognosis, follow-up studies indicate that many patients do not outgrow the disorder but continue to suffer absence seizures well into adulthood. In recent years, there has been considerable research on the neurochemical basis of absence epilepsy. Current theories, including those that implicate gamma-aminobutyric acid, catecholamines, and "endogenous" epileptogens, are summarized; and requirements for an experimentally induced animal model of absence epilepsy are discussed. The majority of behavioral studies of the disorder have concerned the effects of petit mal-type discharges on sensory and cognitive processes. Some of these studies are reviewed; and recent work bearing on these issues, involving event-related brain potentials, is presented. Our review concludes with a discussion of research aimed at the development of electrophysiologically based approaches to the reduction of seizure frequency in patients with absence epilepsy.